Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy (Rhinil-2)

  • STATUS
    Recruiting
  • End date
    Mar 23, 2024
  • participants needed
    24
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Updated on 23 March 2022

Summary

Several studies have reported a deficit and/or a defect in regulatory T cells in allergic subjects, which can be correlated with the allergic responses, especially for respiratory allergies. Low-dose IL-2 (ld-IL2) specifically targets and activates regulatory T cells (Tregs), which are cells that regulate immune responses. Thus by stimulating Tregs, ld-IL2 would control allergic responses.

This study is designed to evaluate the efficacy of ILT-101 (ld-IL-2), compared to placebo, on the nasal response assessed by Total Nasal Symptom Score (TNSS) during a controlled birch allergen exposure.

Description

Primary objective To evaluate the efficacy of ILT-101 (ld-IL-2), compared to placebo, on nasal response on day 40

Secondary objectives To evaluate the efficacy of ILT-101 on rhino-conjunctivitis symptoms, on inflammatory mediators, allergic specific immune responses and safety.

Experimental design This is a monocentric, randomized, placebo controlled, double-blind trial in parallel-groups, evaluating a treatment by ILT-101/placebo, 1 MIU daily for 5 days and 1 MIU every week, until day 36.

Population involved Male or female, aged between 18 and 55 years, with allergic rhinitis to birch pollen.

Number of subjects: 24

Duration of patient participation: 3 months (treatment period: 36 days months, follow-up period: 34 days)

Details
Condition Allergic Rhinoconjunctivitis to Birch Pollen, With a Positive Skin Prick Test to Birch Pollen
Treatment ILT-101 ld-(IL2)
Clinical Study IdentifierNCT03776643
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on23 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

male or female aged between18-55 years
Positive clinical history of seasonal allergic rhinitis to birch pollen for at least 2 consecutive pollinic seasons before inclusion and requiring medication intake with or without GINA 1 associated asthma, with documentation of sensitivity within 12 months before enrollment by : Positive skin prick test (SPT) and validated in vitro tests for specific Immunoglobulin E (IgE); Positive Skin prick test (SPT): wheal for birch pollen ≥ 5 mm in diameter for histamine wheal ≥ 3 mm (positive control) and NaCl reaction < 2 mm (negative control) Positive specific IgE to birch pollen >0.75 kUI/L
Negative beta-HcG pregnancy test at screening visit for women of childbearing age
Normal electrocardiogram without clinically significant abnormalities
Ability to stay in the EEC for up to 4 hours, without any conditions or factors which could make this not possible
Positive nasal response (TNSS≥5) at baseline exposure
Free, informed and written consent signed by the patient and the investigator, before any specific examination required by the study
Affiliation to a social security scheme (beneficiary or assignee)
Negative SARS-CoV-2 test less than 72 hours prior to screening visit

Exclusion Criteria

Asthma: GINA 2 to 5
Eosinophilia > 0.6x109/mL
Any history of anaphylactic reactions
Specific immunotherapy treatment at the moment, including Omalizumab
Specific immunotherapy for birch-pollens within 3 previous years
Use of systemic corticosteroid or others immunosuppressive treatment within previous 6 months
Moderate to severe allergic rhinoconjunctivitis with or without asthma due to grass pollen, if the study is performed during grass pollen season (according to ARIA)
Significant rhinitis, or sinusitis, due to daily contact with other allergen causing symptoms that are expected to coincide with exposures, as assessed by the investigator
Contraindications known to treatment with IL-2
Hypersensitivity to the active substance or to any of the excipients
Immunosuppressed patient
Psychotropic, hepatotoxic, nephrotoxic, myelotoxic or cardiotoxic drugs
Other chronic diseases not clinically controlled
Signs of active infection requiring treatment
Previous history of organ transplantation
Heart failure (≥ grade II, class. NYHA), kidney failure (Cockroft <60 ml/min/1.73m2), liver failure (transaminase> 3N), pulmonary insufficiency (any grade)
Leukocytes <3000 / mm3 lymphocytes <800 / mm3, platelets <80 000 / mm3, Hemoglobin <
0 g/dL or 6.2 mmol/L, red cell blood < 3.5 T/L
Positivity of at least one of the thyroid-specific antibodies (anti-TPO, anti-TG, or anti-TRAKS) associated with an abnormal thyroid workup (TSH, T3, or T4) at inclusion
Chronic uncontrolled arterial hypertension (Systolic BP > 140 mmHg and/or Diastolic BP > 90 mmHg)
Poor venous capital will forbid blood samples
Vaccination with attenuated live vaccine in the month before the inclusion or planned during the study
Vaccination against COVID-19 during the study period or if the 2nd dose of vaccine is planned during the 15 days preceding Visit 3
Surgery in the previous three months or anticipated under study
Participation in other interventional research with study drug in the previous month and during the study
Psychiatric illness or any other concomitant chronic illness or addiction that could interfere with the ability to meet the requirements of the protocol or provide informed consent
Presence or history of unhealed cancer for more than five years, presence or history of healed cancer for less than five years, except carcinoma in situ of the cervix or basal cell carcinoma
Pregnant or lactating women
Men and women of childbearing age without effective contraception during the treatment period
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note